Skip to main content
CVS $85.81 -3.14%
CVS logo
CVS · CVS HEALTH Corp
Track CVS — free
Market Cap
$109.79B
Shares
1.28B
Volume · Nov 17 13.62M Avg daily vol (3M) 9.11M
All webcasts

Annual General Meeting · 2026-05-14

CVS HEALTH Corp (CVS) May 14, 2026 Annual General Meeting Transcript

Concluded May 14, 2026 Audio replay
May 14, 2026 16:38 15 turns
Period
2026-05-14
Runtime
16:38
Sources
2 artifacts

Transcript & audio

16:38 Audio

Good morning, and welcome to the 2026 CVS Health Annual Meeting of Stockholders. I'm Christina Fink, Senior Vice President, Corporate Secretary, and Chief Governance Officer of CVS Health Corporation. In order to allow our stockholders to more easily participate in this meeting, regardless of their geographic location, we are again holding our annual meeting in a virtual-only format. The agenda and the rules of the meeting have been posted in the meeting materials section of the virtual meeting website, along with links to our annual report and our proxy statement. If you have not already voted or wish to change your vote, you can do so at any time until the polls are closed by clicking the vote here button. You can also submit a question or comment at any time using the ask a question box on the website. Please note that, as stated in the rules of the meeting, we ask that you limit your questions to a maximum of two per stockholder and that all questions are germane to the business of the meeting. Questions from multiple stockholders on the same topic or that are otherwise related may be grouped, summarized, and answered together. I'll now turn it over to David Joyner.

J. David Joyner Chairman

Good morning. I'm David Joyner, Chairman of the Board and CEO of CBS Health Corporation, and I'll call this annual meeting of stockholders to order. I'd like to introduce the other members of the company's Board of Directors who are standing for re-election and who are present here today. Fernando Aguirre, former Chairman, President, and CEO of Chiquita Brands International, Dr. Jeff Balzer, President and CEO of Vanderbilt University Medical Center, David Brown, partner of the law firm Nelson Mullins, Alicia DeCredo, President, Emerita Mills College, and a former executive of Eli Lilly, Anne Finucane, Chair of the Board of Rubicon Carbon, and a former Vice Chairman of Bank of America, John Galena, former CFO of Elevance Health, Scott Kirby, CEO, and a member of the Board of Directors of United Airlines, Mike Mahoney, Chairman, CEO, and President of Boston Scientific, Leslie Norwalk, Strategic Counsel at Epstein, Becker and Green, Larry Robbins, CEO and Portfolio Manager of Glenview Capital, Guy Sansone, Chairman and CEO of H2Health, and Doug Shulman, Chairman and CEO of OneMain Financial. I would also like to acknowledge representatives of the company's independent auditors, Ernst and Young, who are joining the meeting today, including our lead audit partner, Stephanie Hollander. Turning to our formal business for the day, Madam Secretary, will you present the list of stockholders of record on March 16, 2026, and tell us that we have a quorum for the transaction of business?

Yes, I can report that the list of stockholders of record on March 16, 2026 has been certified. Beginning on April 3, 2026, a notice of meeting and proxy statement and an annual report were mailed or made available to all such stockholders. And there are present today, either by proxy or in person, holders of at least 1.1 billion shares, representing approximately 89% of the outstanding shares of the company's common stock. And we therefore have a forum.

J. David Joyner Chairman

Thank you, Madam Secretary. I'd now like to appoint John Merva of American Election Services as the Inspector of Elections. Madam Secretary, would you confirm that the oath has been administered?

I can confirm that the oath of office has been administered and executed and is in my possession.

J. David Joyner Chairman

Our principal business today is to act upon the following proposals as set forth in full in the proxy statement mailed or made available to our stockholders beginning on April 3, 2026. Madam Secretary, would you please read a summary of the proposals?

The five proposals before the meeting are as follows. First, a proposal to elect 13 directors. Second, a proposal to ratify the appointment of Ernst & Young as our independent auditors for 2026. Third, an advisory proposal to approve our executive compensation, commonly referred to as say on pay. Fourth, a proposal to approve the company's 2026 incentive compensation plan. And fifth, a stockholder proposal requesting a reduction in the thresholds for our stockholders to act by written consent. Moving to the presentation of the stockholder proposal, we have Glenn Beatty, who will present the proposal submitted by Mr. Shevevan. Mr. Beatty, you have it for three minutes to present the proposal.

Glenn Beatty Other

Proposal 5, overwhelming supermajority protections to apply for a record makes sense. Do not even require a 1% of 25 CVS annual shareholder meeting. 42% is impressive because a large number of CVS shareholders automatically vote against the shareholder. To guard against the CVS Board of Directors, CVS shareholders need an improved ability to act by written consent to help board adopt new strategies. Shareholder ability to act by written consent would be a welcome incentive for Proposal 5.

J. David Joyner Chairman

The company's position on the stockholder proposal is set forth in the proxy statement. Are there any questions regarding the stockholder proposal? All right. As the Secretary announced earlier, voting is available on the virtual meeting website for anyone who has not put in a proxy or who wishes to change his, her, or their vote. If you would like to vote online, please do so now. The polls will close very soon. While the final votes are being cast and counted, I'd like to take this opportunity to acknowledge and thank all of my colleagues at CVS Health for the service and dedication to our company. I'd also like to thank Roger Farah, who is retiring from the board and not standing for a re-election today. Roger has served the board, his committees, and the company with great distinction over the years, including as chair of the board from May 2022 through December 2025, and we wish him all the best. The polls for voting on all matters at this meeting are now closed. No further voting is permitted, and the inspector of elections will consider no further proxies or evidence of voting. The inspector of elections will tabulate the votes cast at this meeting and certify the final results in due course. Returning to the official business of the meeting, Madam Secretary, would you announce the preliminary results of the voting.

The proposal to elect 13 directors has been approved with at least a majority in favor of each nominee. The proposal to ratify the appointment of our auditors has been approved with a majority vote in favor. The proposal regarding our executive compensation has been approved with a majority vote in favor. The proposal regarding our 2026 incentive compensation plan has been approved with a majority vote in favor. The stockholder proposal requesting a reduction in the threshold of our stockholders to act by written consent has not been approved, with a majority vote against. Therefore, subject to the final verification of the vote by the Inspector of Elections, Proposals 1, 2, 3, and 4 have been approved by the required stockholder vote, and Proposal 5 has failed to receive the approval of the required stockholder vote.

J. David Joyner Chairman

Full details of the final votes, as verified by the inspector of elections will be disclosed on a form 8k to be filed with the sec thank you madam secretary and there is no other formal business i hereby adjourn the meeting we're now going to provide a brief business update and then we have some q a thank you for being here today and for your continued support of cvs health help touches every part of our lives and it's personal it It affects our families, our communities, and the people we care about most. And it's foundational, because when health breaks down, everything else becomes harder. But too often, the healthcare experience doesn't reflect how important it really is. It can be complicated, impersonal, and frustrating to navigate, especially when people need clarity and compassion the most. At CVS Health, our focus is straightforward, making healthcare simpler, more affordable, and more connected for the people who rely on us. We're working to solve real problems that drive cost, create friction, and undermine trust in the system, problems that affect patients, employers, providers, and communities every day. Let me share an example. Prior authorizations are meant to support safe, high-quality care, but we saw an opportunity to make the process easier for both members and providers. Today, more than 95% of eligible Aetna prior authorizations are approved within 24 hours, many of them immediately. And at CVS Caremark, about 90% of the eligible prior authorizations are approved within 24 hours. We've also simplified the process by bundling prior authorizations so someone facing a life-changing diagnosis only needs one prior off for the many scans they may have to get. We're using technology to accelerate our ability to seamlessly exchange clinical data with health systems and providers, reducing the administrative burden and speeding up decisions. And through the CVS Health app, you can manage healthcare for your entire family across Aetna, CVS Pharmacy, CVS Caremark, and specialty. Improving access to care is another priority through signify health we bring clinician-led in-home evaluations to members particularly those in rural areas or people who can't easily get to a doctor's office through oak street health we're providing primary care to older adults on medicare often in communities with limited access to care community pharmacy is one of the most accessible and trusted healthcare touch points and we continue to expand the role of our pharmacist and invest in the future of the profession. Affordability and transparency remain central to everything we do. People need to be able to pay for and understand the cost of their care. Together, Cordavas, CVS Caremark, and CVS Specialty offer low-cost biosimilars to patients. We achieved 96% adoption from the high-cost reference brand Humira to the low-list price biosimilar. More than 80% of those members paid $0 out-of-pocket, delivering more than $1.5 billion in savings to our clients and their members. Our innovative industry-leading pricing models, CVS Cost Manage and CVS Caremark True Costs, are bringing greater clarity to drug pricing and reimbursement. These are just a few examples of the ways that we are leading the industry and reimagining health care in America. And when we get it right, we do well by our customers, clients, colleagues, and shareholders. We focused on getting back to basics in our business and being strong operationally. In 2025, we delivered full-year revenue of over $400 billion, adjusted EPS of $6.75, and operating cash flow of $10.6 billion, all of which meaningfully outperformed our initial expectations for the year. This is a direct result of the work we did to ensure each of our businesses is best in class. operational improvements at Aetna, continued strength at Caremark, sustained momentum at CVS Pharmacy, and encouraging progress from our healthcare delivery business. Our ambition is to be the most trusted healthcare company in America. Our purpose is to make healthcare simpler, one person, one family, and one community at a time. That's what people deserve, and that's the work I and my 300,000 colleagues remain focused on delivering. All right, moving on to Q&A. We've got a few questions in queue. Please keep the rules of the meeting in mind if you are submitting a question. Madam Secretary, please read the first question.

David, the first question asks whether the company should maintain its strategic direction as outlined in the proxy statement with a focus on the integrated business model across the different businesses within CVS Health.

J. David Joyner Chairman

Thank you for the question. Let me just reinforce some of the things I mentioned in the business update, but let me start with a simple answer. What people want the most is a connected healthcare experience, and it's what CVS Health does best. The strength of our connected businesses, our experienced leadership team, and more than 300,000 colleagues serving approximately 185 million Americans gives us confidence in our ability to deliver the care people need today while reimagining and improving the experience of tomorrow. Our ambition is to be America's most trusted healthcare company by delivering on our promise to simplify healthcare, one person, one family, and one community at a time. This approach led to a strong financial performance in 2025 with continued momentum this year. Significant progress at Aetna, Caremark continues to lead innovation in the PBM industry, we're exceeding expectations at CVS Pharmacy, and we're positioning the healthcare delivery business for sustainable long-term growth, and we're delivering connected experiences across our organizations. For example, we're improving the prior authorization process, which reduces administrative burden for healthcare providers, takes costs out of the systems, and make it easier for members to get the care they need. We're also supporting members taking GLP-1 medications with late management solutions that help achieve the best clinical outcomes at the lowest net cost. We're enhancing our formulary strategy to continue balancing the cost and coverage by prioritizing clinically effective therapies, delivering more than $1.5 billion in client savings through biosimilar adoption. We're also using technology to improve the consumer experience. Our pharmacists use advanced AI tools to help identify patients with low adherence. We then re-engage those patients. Forty-five percent of our retail customers engage with us on their digital device. 75% of calls to pharmacy resolve quickly with conversational AI, and AI is giving nurses about 90 minutes back every day. And 95% of the Aetna inquiries and 86% of Caremark inquiries are resolved quickly online. Conversational AI resolves many of the others. When a Caremark or Aetna member needs to speak to a representative, those reps are assisted by AI to accelerate the understanding and resolution of the issue. And if the member is both at Caremark and at a member, that same representative can resolve questions that span across both companies. Finally, we believe engagement is a game changer for better health. As we work together across CVS Health to create a simpler experience, we know the people we serve will be more engaged in achieving better health.

Thank you, David. We have also received questions regarding our executive compensation program. Our executive compensation philosophy and practices reflect our commitment to paying for performance, both short and long-term, measured against challenging internal financial targets that take into account our results relative to those of our peer companies, as well as industry and market conditions. More information is available starting on page 41 of our proxy statement. Information about our 2026 equity awards begins on page 63 of our proxy statement. Additional information about our 2026 Executive Compensation Program will be found in our 2027 proxy statement. There are no additional questions in the queue that meet the requirements of the rules of the meeting. Thank you for attending our annual meeting of stockholders and for your continued support of CDS Health.

J. David Joyner Chairman

This now concludes the meeting. Thank you for joining, and have a pleasant day.

Full-screen source Call document